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Knapland: Synthetic Cells, Synthetic Life, and Inheritance

SYNTHETIC CELLS, SYNTHETIC LIFE, AND
INHERITANCE
Kristine S. Knaplund*
I. INTRODUCTION
“This is the first self-replicating species that we’ve had on the
planet whose parent is a computer.”1
In May 2010, J. Craig Venter and his team announced the creation of
a “synthetic cell,” or as the team described it, a process of “synthesis,
assembly, cloning, and successful transplantation [of a synthetic
genome] to create a new cell controlled by this synthetic genome.”2 They
chose to start with a simple bacterium, Mycoplasma genitalium (“M.
genitalium”) because it has “the smallest complement of genes of any
known organism capable of independent growth in the laboratory.”3
Using chemical enzymes and live bacteria, they were able to replicate the
genome sequence of M. genitalium and then transplant it into a natural
cell controlled by the synthetic genome.4 Although the team had not
created a new cell entirely from chemicals, their research demonstrates
progress towards that end.
The creation of a synthetic genome is an important advancement in
synthetic biology, “an emerging field of research that combines elements
of biology, engineering, genetics, chemistry, and computer science.”5
Synthetic biology research often begins with a “[t]op-down” approach,
using existing genes and other materials as parts to be analyzed or
possibly reconfigured.6 For Venter’s team, that included sequencing the

*
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acknowledge the outstanding work of her research assistants David Peromsik and Jennifer
Vagle and research librarian Jennifer Allison, the Dean’s Summer Research Fund, and the
participants in the Valparaiso Law Review Symposium on Bioethics, Law and Synthetic
Biology.
1
See generally J. Craig Venter Inst., Craig Venter Unveils “Synthetic Life”, TED: IDEAS
WORTH SPREADING (May 2010), http://www.ted.com/talks/craig_venter_unveils_
synthetic_life.html (announcing the first fully functioning, reproducing cell controlled by
synthetic DNA).
2
Daniel G. Gibson et al., Creation of a Bacterial Cell Controlled by a Chemically Synthesized
Genome, 329 SCI. 52, 55 (2010).
3
Id. at 52.
4
Id. at 55–56.
5
PRESIDENTIAL COMM’N FOR THE STUDY OF BIOETHICAL ISSUES, NEW DIRECTIONS: THE
ETHICS OF SYNTHETIC BIOLOGY AND EMERGING TECHNOLOGIES 36 (2010),
http://www.bioethics.gov/documents/synthetic-biology/PCSBI-Synthetic-BiologyReport-12.16.10.pdf [hereinafter NEW DIRECTIONS].
6
Id.
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genome of M. genitalium in 1995.7 Synthetic biology also includes
“[b]ottom-up” research to create new organisms using only chemical
reagents.8
Synthetic biology is used today in the field of assisted reproduction
to analyze existing genes. An example of such “top-down” synthetic
biology is preimplantation genetic diagnosis (“PGD”) to screen for
human immunodeficiency virus, cystic fibrosis, or other diseases.9 This
Article will focus on the “bottom-up” use of synthetic biology in the
context of assisted reproduction. One day, scientists may be able to
create synthetic human gametes or embryos for purposes of assisted
reproduction.10 It is impossible to forecast when this may occur; as the
2010 Presidential Commission for the Study of Bioethical Issues noted,
“the pace of discovery is unpredictable.”11 But instead of deferring the
discussion until synthetic sperm or ova actually appear, we should
anticipate the risks and benefits now. This Article will focus on the
practical and regulatory issues that may encourage or inhibit the use of
Venter’s technology to create synthetic gametes and the legal issues of
parentage and inheritance for a synthetically created child.
Part II of this Article sets the stage by briefly discussing infertility in
the United States, the development of assisted reproduction technologies
to counteract infertility, and other additional uses of assisted
reproductive technologies (“ART”) such as PGD, which is also used by
fertile couples. Part III examines the existing laws and regulations that
may apply to the development of synthetic human gametes or embryos.
With the market demands from Part II and the regulatory structure from
Part III in mind, Part IV will look at the parentage and inheritance issues
if a synthetic gamete results in a living child. Part V concludes the
Article by exploring two approaches to regulatory issues.
This Article will follow Recommendation Fifteen from the
Presidential Commission regarding Information Accuracy:

Gibson et al., supra note 2, at 52.
NEW DIRECTIONS, supra note 5, at 36.
9
Id. at 66. Preimplantation genetic diagnosis (“PGD”) is used to screen for certain
genetic or chromosomal diseases, while preimplantation genetic screening (“PGS”) can be
used for other purposes, such as genetic characteristics. Jaime King, Predicting Probability:
Regulating the Future of Preimplantation Genetic Screening, 8 YALE J. HEALTH POL’Y L. &
ETHICS 283, 284 (2008). This Article will use the term “PGD” to encompass both concepts.
10
Already, “new developments in basic science have led to new understandings about
how to create and manipulate human gametes—only recently, scientists have discovered
how to create artificial mouse eggs from embryonic stem cells.” Gail H. Javitt & Kathy
Hudson, Regulating (for the Benefit of) Future Persons: A Different Perspective on the FDA’s
Jurisdiction to Regulate Human Reproductive Cloning, 2003 UTAH L. REV. 1201, 1208.
11
NEW DIRECTIONS, supra note 5, at 67.
7
8
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When discussing synthetic biology, individuals and
deliberative forums should strive to employ clear and
accurate language. The use of sensationalist buzzwords
and phrases such as “creating life” or ”playing God”
may initially increase attention to the underlying science
and its implications for society, but ultimately such
words impede ongoing understanding of both the
scientific and ethical issues at the core of public debates
on these topics. To further promote public education
and discourse, a mechanism should be created, ideally
overseen by a private organization, to fact-check the
variety of claims relevant to advances in synthetic
biology.12
II. INFERTILITY AND ASSISTED REPRODUCTION
The infertility industry in the United States is big business. A
Centers for Disease Control and Prevention (“CDC”) report presented
the latest data on infertility:
•

•

Of the approximately 62 million women of reproductive
age in 2002, about 1.2 million, or 2%, had an infertilityrelated medical appointment within the previous year
and an additional 10% had received infertility services at
some time in their lives. (Infertility services include
medical tests to diagnose infertility, medical advice and
treatments to help a woman become pregnant, and
services other than routine prenatal care to prevent
miscarriage.)
Additionally, 2.1 million couples or about 7% of married
couples, in which the woman was of reproductive age
reported that they had not used contraception for 12
months and the woman had not become pregnant.13

Just one aspect of assisted reproduction, the exchange of eggs (ova),
has been estimated to be worth $4.5 billion in the United States.14
Id. at 15.
CTRS. FOR DISEASE CONTROL & PREVENTION, U.S. DEP’T OF HEALTH & HUMAN SERVS.,
2006 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES: NATIONAL SUMMARY AND
FERTILITY CLINIC REPORTS 3 (2008), http://www.cdc.gov/ART/ART2006/508PDF/
2006ART.pdf [hereinafter 2006 ART SUCCESS RATES] (providing data from the 2002
National Survey of Family Growth).
14
Sunni Yuen, Comment, An Information Privacy Approach to Regulating the Middlemen in
the Lucrative Gametes Market, 29 U. PA. J. INT’L L. 527, 546 (2007).
12
13
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Donated ova are used in about 12% of the assisted reproduction
procedures reported to the CDC.15
The first widely available technology for infertility was assisted or
artificial insemination (“AI”), in which semen is inserted into the
woman’s cervix or uterus via syringe. The first report of AI for human
use was published in 1884, but the technique had been used long before
in animal husbandry.16
AI solves only a limited range of fertility problems, prompting
scientists to work on other methods of assisted reproduction in which
both the sperm and the egg (ovum) can be handled in the laboratory.
Worries about possible birth defects, the discarding of gametic material,
and other issues led to a ban on the use of federal funds for such research
in 1973, but research funded from non-federal sources and in other
countries continued.17 Drs. Steptoe and Edwards of the United Kingdom
radically altered the discussion when they introduced the first “test
tube” baby in a 1978 press release.18 Similar to Venter’s synthetic
genome, the success of in vitro fertilization (“IVF”), in which the egg and
sperm are joined in a Petri dish and later implanted in a woman’s
uterus,19 was termed the “medical media event of the year” in a Hastings
Center Report.20 After roughly one hundred attempts, the process ended
successfully with the birth of Louise Brown.21 Once an apparently
healthy baby was born, the U.S. Ethics Advisory Board, at the urging of
Joseph Califano, Secretary of Health, Education, and Welfare,22
recommended reversing the ban on federal research funds, but otherwise
left oversight of IVF to the states.23 Since 1978, more than three million

2006 ART SUCCESS RATES, supra note 13, at 56.
Carolyn Sappideen, Life After Death—Sperm Banks, Wills and Perpetuities, 53 AUSTL. L. J.
311, 311 (1979).
17
Robert Toth, Panel To Consider Ethics of Test-Tube Baby Research, L.A. TIMES, Sept. 15,
1978, at B1.
18
1978: First ‘Test Tube Baby’ Born, BBC: ON THIS DAY http://news.bbc.co.uk/
onthisday/hi/dates/stories/july/25/newsid_2499000/2499411.stm (last visited Apr. 14,
2011).
19
See Kerry Lynn Macintosh, Brave New Eugenics: Regulating Assisted Reproductive
Technologies in the Name of Better Babies, 2010 U. ILL. J.L. TECH. & POL’Y 257, 264–65
(explaining the standard IVF procedure).
20
Daniel Callahan, In Vitro Fertilization: Four Commentaries, HASTINGS CTR REP., Oct.
1978, at 7.
21
Walter Sullivan, Doctor in Laboratory Conception Says First 100 Attempts Failed, N.Y.
TIMES, Dec. 1, 1978, at A21.
22
Robert Toth, Califano Urges Debate on Baby Research, L.A. TIMES, Sept. 16, 1978, at A2.
23
Dena Kleiman, Anguished Search To Cure Infertility: Medical Advances Offer New Hope,
But Infertility Affects More Couples Than Ever, N.Y. TIMES, Dec. 16, 1979, at SM38.
15
16
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babies have been born worldwide using assisted reproduction
technologies.24
Cryopreservation, the ability to store sperm, ova, and embryos for
later use, is widely used today. The ability to successfully freeze sperm
has been available for over fifty years.25 However, cryopreservation of
embryos is more recent and widely available, with 100% of fertility
clinics reporting to the CDC that they offer this service as part of assisted
reproduction.26 Freezing unfertilized eggs is now possible, but it is
considered experimental by the American Society of Reproductive
Medicine and the American College of Obstetrics and Gynecologists.27
Sperm and ova can be retrieved after a person’s death or while a
person is in a persistent vegetative state. Cappy Rothman first reported
his method to extract sperm postmortem in 1980.28 Although it is
possible to retrieve ova after a woman has died, no such instance has
been reported to date. A recent article in the New England Journal of
Medicine considered the ethics of granting a husband’s request to keep
his wife, who was on life support, alive long enough to retrieve her eggs;
the request was ultimately denied.29
Along with ART such as IVF, clinics also offer services evidencing
“top-down” synthetic biology such as sex selection and PGD.
Commercial techniques such as MicroSort separate male-producing
sperm from female-producing sperm.30 The woman is then inseminated
with sorted sperm of the desired gender.31 PGD involves removing one
cell from an early-stage embryo and testing that cell either for various
traits including sex or for genes that cause diseases such as cystic
fibrosis.32

Macintosh, supra note 19, at 259.
Sappideen, supra note 16, at 311.
26
See 2006 ART SUCCESS RATES, supra note 13, at 89 (finding that 100% of the reporting
clinics offered cryopreservation of embryos as one of their services).
27
Judy Foreman, Health Sense: Success Rate Elusive on Frozen Eggs, L.A. TIMES, Aug. 16,
2010, at E3.
28
Cappy Miles Rothman, A Method for Obtaining Viable Sperm in the Postmortem State, 34
FERTILITY & STERILITY 512, 512 (1980).
29
David M. Greer et al., Case 21-2010—A Request for Retrieval of Oocytes from A 36-YearOld Woman with Anoxic Brain Injury, 363 NEW ENG. J. MED. 276, 279, 282 (2010).
30
See MicroSort®, GENETICS & IVF INST., http://www.microsort.net (last visited Apr. 3,
2011) (discussing the Microsort technique, related clinical studies, and eligibility
requirements for interested parties).
31
Rob Stein, A Boy for You, a Girl for Me: Technology Allows Choice, WASH. POST, Dec. 14,
2004, at A1.
32
Judy Peres, High Stakes of High-Tech Medicine: Who Is At Fault When Cutting-Edge
Technology Fails and Who Must Pay the Price? A Couple’s Lawsuit Looks at the Issues of Consent
and Experimentation in Assisted Reproductive Technologies, CHI. TRIB., Nov. 1, 1998, at C1.
24
25
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Current techniques allow ART users to select an embryo with the
desired characteristics and discard another. If a synthetic sperm or
ovum is created, the user could select for a wide range of genetic
characteristics, even those not present in the intended parents.
III. EXISTING REGULATIONS
If researchers begin using Venter’s techniques to create a synthetic
gamete, would federal and state regulations encourage or hinder their
efforts? Existing laws and regulations on synthetic genomes primarily
focus on biosafety concerns to ensure that the new creations are not
released into the wild and that villains are not trying to concoct
hazardous substances such as anthrax or small pox. The PATRIOT Act33
expanded 18 USC § 175 (prohibitions with respect to biological weapons)
by adding the following subsection:
(b) ADDITIONAL OFFENSE.—Whoever knowingly
possesses any biological agent, toxin, or delivery system
of a type or in a quantity that, under the circumstances,
is not reasonably justified by a prophylactic, protective,
bona fide research, or other peaceful purpose, shall be
fined under this title, imprisoned not more than 10
years, or both. In this subsection, the terms “biological
agent” and “toxin” do not encompass any biological
agent or toxin that is in its naturally occurring
environment, if the biological agent or toxin has not
been cultivated, collected, or otherwise extracted from
34
its natural source.
Regulations issued by federal agencies such as the CDC, the
Department of Agriculture, and the Department of Commerce have
listed the biological agents, toxins, and so on that would violate the
PATRIOT Act.35 Vendors synthesizing DNA use screening software
33
Uniting and Strengthening America by Providing Appropriate Tools Required to
Intercept and Obstruct Terrorism (USA PATRIOT Act) Act of 2001, Pub. L. No. 107-56, 115
Stat. 272 (codified in scattered sections of the U.S.C.).
34
18 U.S.C. § 175(b) (2006).
35
See 7 C.F.R. § 331.3 (2010) (providing the Department of Agriculture’s list of toxins
and agents capable of producing harm to plants and plant products); 9 C.F.R. § 121.3 (2010)
(providing the Department of Agriculture’s list of toxins and agents capable of producing
harm to public health and safety, animals, and animal products); 15 C.F.R. pt. 774 (2010)
(outlining the relevant sections: 1C351, 1C353, 1C354 and 1C991); 42 C.F.R. § 73.3 (2011)
(listing the specific agents and toxins considered by the Department of Health and Human
Services to pose serious risks and dangers to the public).
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such as “BlackWatch” to test whether the requested DNA sequence is on
the list of banned agents.36 The list of pathogens tested includes seventyfive organisms and twenty-two toxins:37
Host
Pathogen Type
Viruses
Bacteria
Fungi
Rickettsiae
[parasite
related]
Prions
[proteins
that
cause degenerative brain
disease, like mad cow]
Toxins

Human/
Animal

Animal
Only

Plant

Total

19
15
2
4

12
3
0
0

2
8
2
9

33
26
11
4

0

1

0

1

22

0

0

22

These current regulations would have little effect on the creation of
synthetic sperm or ovum; although researchers would need to check
their DNA sequences against the list of pathogens, it is not their goal to
create one of them. A more significant impact on synthetic gamete
research may be found in the regulations on assisted reproduction,
which impose limitations on sperm banks, fertility clinics, and other
providers of infertility services. How much of an impact these
regulations would have depends in part on whether creating a synthetic
gamete is seen as akin to processes such as PGD or more like oocyte
transfer or cloning. These questions, in turn, require examination of the
regulations regarding both gametes and embryos. Most regulation today
is focused on controlling communicable diseases, inhibiting the sale of
genetic material, or avoiding the destruction of embryos. IVF clinics
report to the CDC, and states have various regulations incidentally
affecting IVF, such as bans on the sale of ova or refusals to enforce
surrogacy contracts. However, generally speaking, the free market has
reigned.38 By determining that the procedure used by Louise Brown’s
Robert Jones, Sequence Screening, in WORKING PAPERS FOR SYNTHETIC GENOMICS: RISKS
BENEFITS FOR SCIENCE AND SOCIETY 1, 2 (MS Garfinkel et al. eds., 2007), available at
http://www.jcvi.org/cms/fileadmin/site/research/projects/synthetic-genomicsreport/Jones-Sequence-Screening.pdf.
37
Id. at 10.
38
See Jaime King, Predicting Probability: Regulating the Future of Preimplantation Genetic
Screening, 8 YALE J. HEALTH POL’Y L. & ETHICS 283, 357 (2008) (noting that “a technological
revolution in reproduction is coming” and suggesting that the time to regulate is now).
36

AND
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mother was a treatment for her infertility rather than medical
experimentation on human subjects, the IVF industry has been allowed
to develop with little restriction in the United States.
A. ART/Embryos
In 2004, the President’s Council on Bioethics observed in its report,
Reproduction & Responsibility: The Regulation of New Biotechnologies, that
new reproductive technologies “move from the experimental context to
clinical
practice
with
relatively
little
oversight
or
deliberation. . . . Current professional guidelines dictate only that there
be two peer-reviewed papers showing an acceptable risk-benefit ratio
before the status of a new practice is elevated from ‘experimental’ to
‘clinically acceptable.’”39 PGD and preimplantation genetic screening
(“PGS”)40 have remained largely unregulated, arguably due to political
reasons41 and constitutional concerns regarding intrusion upon
recognized procreative liberties.42
Less controversial experimental
techniques such as intracytoplasmic sperm injection “have entered
clinical practice with limited prior testing and limited monitoring of their
effects on the children produced with their aid.”43 Consequently, ART
remains largely unregulated by both the federal government and states.44
PRESIDENT’S COUNCIL ON BIOETHICS, REPRODUCTION & RESPONSIBILITY:
THE
REGULATION OF NEW BIOTECHNOLOGIES 176 (2004) [hereinafter 2004 PRESIDENT’S COUNCIL
REPORT]. Furthermore, “[o]nce in practice, these techniques are used at clinicians’
discretion, with little or no external oversight. Use of effective technologies becomes
widespread rapidly.” Id.
40
See King, supra note 38, at 290–96 (describing the technologies involved in PGS).
41
Jaime King states that
[o]ne of the main reasons the United States has not regulated PGS is
because American politicians do not find it politically advantageous.
The lack of political interest has occurred for three reasons: 1) few
studies have demonstrated harm to children from PGS; 2) the current
technological limitations of PGS have restricted both patient demand
and the frequency of its use for controversial purposes; and 3) PGS
regulation is politically divisive.
As a result, politicians have
effectively tabled the issue until a significant harm or risk demands
political action.
Id. at 321.
42
See id. at 326–29 (discussing the constitutional considerations regarding procreative
liberties); see also Susannah Baruch, Preimplantation Genetic Diagnosis and Parental
Preferences: Beyond Deadly Disease, 8 HOUS. J. HEALTH L. & POL’Y 245, 261–62 (2008) (noting
that the political and legal challenges on regulating the use of PGD are similar to the
debates over abortion).
43
2004 PRESIDENT’S COUNCIL REPORT, supra note 39, at 174–75. Intracytoplasmic sperm
injection (“ICSI”) is “a procedure in which a single sperm is injected directly into an
egg . . .” 2006 ART SUCCESS RATES, supra note 13, at APPENDIX B, GLOSSARY OF TERMS].
44
See infra Parts III.A.1 and III.A.2 (discussing federal and state regulation of ART).
39

https://scholar.valpo.edu/vulr/vol45/iss4/3

Knapland: Synthetic Cells, Synthetic Life, and Inheritance

2011]
1.

Synthetic Cells, Synthetic Life, and Inheritance

1369

Federal Regulation of ARTs

Currently, there are three significant restrictions at the federal level
regarding research on embryos and the practice of ART: (1) the
reporting requirement administered by the CDC; (2) a ban on federal
funding for research involving the destruction of human embryos; and
(3) the regulation of practices such as somatic cell nuclear transfer,
commonly known as cloning.
a.

The CDC Reporting Requirement

The Fertility Clinic Success Rate and Certification Act of 1992
(“FCSRCA”)45 requires each ART program handling ova or embryos to
report annually to the CDC the “(1) pregnancy success rates achieved by
such program through each assisted reproductive technology, and (2) the
identity of each embryo laboratory . . . used by such program and
whether the laboratory is certified . . . or has applied for such
certification.”46 The FCSRCA further directs the CDC to annually
publish, among other information
pregnancy success rates reported to the [CDC] under
section 263a-1(a)(1) of this title and, in the case of an
assisted reproductive technology program which failed
to report one or more success rates as required under
such section, the name of each such program and each
pregnancy success rate which the program failed to
report.47
Although the FCSRCA instructs the CDC to “develop a model
program for the certification of embryo laboratories . . . to be carried out
by the States,”48 it further provides that “[i]n developing the certification
program, the [CDC] may not establish any regulation, standard, or
requirement which has the effect of exercising supervision or control
over the practice of medicine in assisted reproductive technology
programs.”49
45
Fertility Clinic Success Rate and Certification Act of 1992, Pub. L. No. 102-493, 106
Stat. 3146 (codified as amended at 42 U.S.C. §§ 263a-1 to -7 (2006)).
46
42 U.S.C. § 263a-1(a)(1) to (2). The Act defines “assisted reproductive technology” as
techniques handling ova or embryos, and thus excludes sperm banks and assisted
insemination, in which only the sperm is handled outside the body. 42 U.S.C. § 236a-7(1).
47
Id. § 263a-5(1)(A).
48
Id. § 263a-2(a)(1).
49
Id. § 263a-2(i)(1). Similarly, the FCSRCA provides that “[i]n adopting the certification
program, a State may not establish any regulation, standard, or requirement which has the
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If an ART clinic began using synthetic gametes or embryos, the clinic
would simply need to include the outcomes of the implantations in its
statistics. One question would arise as to which category to place the
synthetic materials; the current report is broken into two parts: those
with “non-donor eggs” and those with “donor eggs.” There is no
separate category for “donor sperm.” Thus if synthetic sperm were used
to create the embryo through in vitro fertilization, that fact would go
unmentioned. If a synthetic egg were used, perhaps a third reporting
category would be created, or the synthetic ovum might be included in
the “donor egg” category since the birth mother would not be the genetic
mother in either case.
b.

The Ban on Federal Funding

Since 1996, appropriations acts have been restricted by the DickeyWicker Amendment, which prohibits the National Institutes of Health
(“NIH”) from funding research that results in the destruction of human
embryos.50 Specifically, Dickey-Wicker bans the use of federal funds for
the following:
(1) the creation of a human embryo or embryos for
research purposes; or
(2) research in which a human embryo or embryos
are destroyed, discarded, or knowingly subjected to risk
of injury or death greater than that allowed for research
on fetuses in utero under 45 C.F.R. 46.208(a)(2) and 42
U.S.C. 289g(b).51

effect of exercising supervision or control over the practice of medicine in assisted
reproductive technology programs.” Id. § 263a-2(i)(2).
50
Balanced Budget Downpayment Act, I, Pub. L. No. 104-99, § 128, 110 Stat. 26, 34
(1996). This ban has been included annually in subsequent appropriations bills. See, e.g.,
Consolidated Appropriations Act, 2001, Pub. L. No. 106-554, § 510(a), 114 Stat. 2763, 2763A71 (2000); Consolidated Appropriations Act, 2000, Pub. L. No. 106-113, § 510(a), 113 Stat.
1501, 1501A-275 (1999); Omnibus Consolidated and Emergency Supplemental
Appropriations Act, 1999, Pub. L. No. 105-277, § 511(a), 112 Stat. 2681, 2681-386 (1998);
Departments of Labor, Health and Human Services, Education, and Related Agencies
Appropriations Act, 1998, Pub. L. No. 105-78, § 513(a), 111 Stat. 1467, 1517 (1997); Omnibus
Consolidated Appropriations Act, 1997, Pub. L. No. 104-208, § 512(a), 110 Stat. 3009, 3009270 (1996).
51
Balanced Budget Downpayment Act, I § 128. Courts have defined “the term ‘research’
as used in the Dickey-Wicker Amendment [as having] only one meaning, i.e., ‘a systematic
investigation, including research development, testing and evaluation, designed to develop
or contribute to generalizable knowledge.’” Sherley v. Sebelius, 704 F. Supp. 2d 63, 70
(D.D.C. 2010) (quoting 45 C.F.R. § 46.102(d) (2009)); see also 42 U.S.C. § 289g(b) (explaining
that the risk standard is to “be the same for fetuses which are intended to be aborted and
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The Amendment further provides that “the phrase ‘human embryo or
embryos’ shall include any organism, not protected as a human subject
under 45 C.F.R. 46 as of the date of enactment of this Act, that is derived
by fertilization, parthenogenesis, cloning, or any other means from one
or more human gametes.”52
President Barack Obama attempted in 2009 to remove restrictions
against federal funding for research that results in the destruction of
human embryos.53 The Dickey-Wicker Amendment, however, arguably
prohibits funding for such research,54 which also extends to cloning
research.55
The Dickey-Wicker Amendment likely would require
research on synthetic gametes joined with human gametes to be
conducted with non-federal funds. Thus, the impact could be similar to
that found in the 1970s when the federal government banned the use of
federal funds for research on in vitro fertilization: the research
continued with non-federal funds and in other countries, resulting in the
birth of Louise Brown in Great Britain in 1978.
If both synthetic sperm and synthetic ovum were used to create a
synthetic embryo, the Dickey-Wicker Amendment would not apply. The
amendment defines human embryos to include any organism derived by
“any other means from one or more human gametes,”56 but a synthetic
embryo has no human gametes.
c.

FDA Regulation of Human Reproductive Cloning

The FDA has effectively banned research on cloning in the United
States since 1998.57 Somatic cell58 nuclear transfer (“SCNT”) cloning
“entails removing the original nucleus from an egg cell and replacing
that nucleus with one from a somatic cell, such as a skin cell. The egg
cell, now containing a new (for the egg cell) nucleus, is then induced to
fetuses which are intended to be carried to term”); 45 C.F.R. § 46.204(b) (2010) (prohibiting
research on fetuses in utero unless “the risk to the fetus is not greater than minimal and the
purpose of the research is the development of important biomedical knowledge which
cannot be obtained by any other means”).
52
Balanced Budget Downpayment Act, I § 128.
53
See Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 11, 2009).
54
See Sherley, 704 F. Supp. 2d at 70 (granting a preliminary injunction enjoining the
Secretary of Health and Human Services from implementing NIH guidelines allowing
embryonic stem cell research after finding that plaintiffs were likely to succeed on the
merits of their claim that the guidelines violated the Dickey-Wicker Amendment).
55
JUDITH A. JOHNSON & ERIN D. WILLIAMS, CONG. RESEARCH SERV., RL 31358, HUMAN
CLONING 7–8 (2006), available at http://www.fas.org/sgp/crs/misc/RL31358.pdf.
56
Balanced Budget Downpayment Act, I § 128.
57
Javitt & Hudson, supra note 10, at 1202.
58
Somatic cells are non-reproductive cells, while germ cells are reproductive cells
(sperm cells and egg cells). Id. at 1214.
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divide under laboratory conditions to form an embryo.”59 If the embryo
is subsequently implanted in a uterus and “successfully gestated, the
result is an organism that is a virtually identical genetic copy (with the
exception of the mitochondrial DNA) of the source of the somatic cell.”60
If researchers wish to perform SCNT, they must first apply to the
FDA for an investigational new drug application. The FDA has stated
that it will not approve an application for such research until the safety
concerns involved with cloning have been resolved.61
Although a synthetic embryo might well raise safety concerns, the
process to create one would not involve cloning. Unlike SCNT, the
synthetic gamete would be joined with either a human gamete or
another synthetic gamete, so that the resulting embryo would not be an
identical genetic copy of the synthetic material.
The FDA also has authority to regulate the fertility drugs and
medical devices used in ART, including “instrumentation intended for
use in IVF and related ART procedures.”62 This could limit the research
into synthetic genetic material only if drugs or medical devices not
currently used in assisted reproduction are created specifically for this
synthetic process. This seems unlikely to occur.
2.

State Regulation of ARTs

Although states have been more active than the federal government
in regulating research on human embryos and fetuses, existing state laws
would have limited impact on the creation of synthetic gametes or
embryos. Some states prohibit research on human embryos and
fetuses,63 others prohibit the sale of embryos and fetuses,64 and others
Id. at 1203.
Id. at 1204.
61
Id. at 1202.
62
Obstetric and Gynecologic Devices; Reclassification and Classification of Medical
Devices Used for In Vitro Fertilization and Related Assisted Reproduction Procedures, 63
Fed. Reg. 48,428, 48,428 (Sept. 10, 1998) (to be codified at 21 C.F.R. pt. 884).
63
See, e.g., LA. REV. STAT. ANN. § 9:122 (2008) (“The use of a human ovum fertilized in
vitro is solely for the support and contribution of the complete development of human in
utero implantation. No in vitro fertilized human ovum will be farmed or cultured solely
for research purposes or any other purposes.”); ME. REV. STAT. ANN. tit. 22, § 1593(1) (2004)
(“A person may not use, transfer, distribute or give away a live human fetus, whether
intrauterine or extrauterine, or any product of conception considered live born, for
scientific experimentation or for any form of experimentation.”); N.M. STAT. ANN. § 24-9A3(A) (LexisNexis 2007) (“No fetus shall be involved as a subject in any clinical research
activity unless the purpose of the activity is to meet the health needs of the particular fetus
and the fetus will be placed at risk only to the minimum extent necessary to meet such
needs or no significant risk to the fetus is imposed by the research activity.”); see also N.M.
STAT. ANN. § 24-9A-5(A) (outlining very limited exceptions to the general ban on “clinical
59
60
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impose mandatory reporting requirements on IVF facilities65 or require
IVF facilities to adhere to professional society guidelines.66 At least one
state has set forth rules for the performance of IVF and has established
eligibility requirements for IVF recipients.67 Louisiana goes so far as to
identify embryos as juridical persons and prohibit their intentional
destruction.68 In addition, as of January 2008, fifteen states regulated
research activity involving fetuses, live-born infants or pregnant women”); R.I. GEN. LAWS
§ 11-54-1(a) (2002) (“No person shall use any live human fetus, whether before or after
expulsion from its mother’s womb, for scientific, laboratory research, or other kind of
experimentation.”); S.D. CODIFIED LAWS § 34-14-17 (2004) (“No person may knowingly
conduct nontherapeutic research that subjects a human embryo to substantial risk of injury
or death.”).
64
See, e.g., IND. CODE ANN. § 35-46-5-3(a) (West Supp. 2010) (“A person who knowingly
or intentionally purchases or sells a human ovum, zygote, embryo, or fetus commits
unlawful transfer of a human organism, a Class C felony.”); LA. REV. STAT. ANN. § 9:122
(2008) (“The sale of a human ovum, fertilized human ovum, or human embryo is expressly
prohibited.”); S.D. CODIFIED LAWS § 34-14-17 (2004) (“No person may sell or transfer a
human embryo with the knowledge that the embryo will be subjected to nontherapeutic
research.”).
65
See 18 PA. CONS. STAT. ANN. § 3213(e) (West 2000) (“All persons conducting, or
experimenting in, in vitro fertilization shall file quarterly reports with the department,
which shall be available for public inspection and copying . . . .”).
66
In Louisiana,
[o]nly medical facilities meeting the standards of the American
Fertility Society and the American College of Obstetricians and
Gynecologists and directed by a medical doctor licensed to practice
medicine in this state and possessing specialized training and skill in
in vitro fertilization also in conformity with the standards established
by the American Fertility Society or the American College of
Obstetricians and Gynecologists shall cause the in vitro fertilization of
a human ovum to occur. No person shall engage in in vitro
fertilization procedures unless qualified as provided in this Section.
LA. REV. STAT. ANN. § 9:128 (2008).
67
In New Hampshire,
[i]n vitro fertilization and preembryo transfer shall be performed
in accordance with rules adopted by the department of health and
human services and shall be available only to a woman:
I.
Who is 21 years of age or older;
II. Who
has
been
medically
evaluated
and
the
results . . . demonstrate the medical acceptability of the woman to
undergo the . . . procedure;
III. Who receives counseling . . . and provides written
certification of the counseling and evaluation to the health care
provider performing the . . . procedure; and
IV. Whose husband, if the recipient is married, receives
appropriate counseling . . . and [satisfies other requirements].
N.H. REV. STAT. ANN. § 168-B:13 (LexisNexis 2010).
68
In Louisiana,
[a] viable in vitro fertilized human ovum is a juridical person
which shall not be intentionally destroyed by any natural or other
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cloning in some way, either by banning the use of public funds for
cloning or by outright prohibition of therapeutic and/or reproductive
cloning.69 A proposed law, Georgia’s Ethical Treatment of Embryos Act,
sought “[t]o amend Chapter 7 of Title 19 of the Official Code of Georgia
Annotated . . . to provide that it shall be unlawful for any person or
entity to intentionally or knowingly create or attempt to create an in vitro
human embryo by any means other than fertilization of a human egg by
a human sperm or intracytoplasmic sperm injection.”70 None of these
enacted or proposed state laws would impact research on synthetic
genetic materials as long as the creation of synthetic gametes is not
considered “research,” and the resulting embryo is not defined as
“human.”
3.

Professional Societies’ Recommendations on ARTs

Professional societies would likewise have little impact on the
research of synthetic embryos. The American Society for Reproductive
Medicine (“ASRM”), in conjunction with its sister organization, the
Society for Assisted Reproductive Technology, “provides guidance by
means of published statements, opinions, and guidelines issued by its
practice and ethics committees. The chief values ASRM seeks to promote
through its opinions and guidelines are safety (of ART participants),
efficacy (of techniques and procedures), and privacy (of ART
patients).”71 ASRM issues both practice guidelines and ethical guidelines
on a variety of issues related to ART.72 Because compliance is voluntary,
however, professional guidelines are generally unenforceable.73
juridical person or through the actions of any other such person. An in
vitro fertilized human ovum that fails to develop further over a thirtysix hour period except when the embryo is in a state of
cryopreservation, is considered non-viable and is not considered a
juridical person.
LA. REV. STAT. ANN. § 9:129 (2008).
69
See Human Cloning Laws, NAT’L CONF. ST. LEGISLATURES (Jan. 2008),
http://www.ncsl.org/default.aspx?tabid=14284.
Those fifteen states are Arizona,
Arkansas, California, Connecticut, Indiana, Iowa, Maryland, Massachusetts, Michigan,
Missouri, New Jersey, North Dakota, Rhode Island, South Dakota, and Virginia. Id.
70
S.B. 169, 150th Gen. Assemb., Reg. Sess. (Ga. 2009), available at http://www1.legis.ga.
gov/legis/2009_10/pdf/sb169.pdf. The Act passed the Georgia State Senate by a vote of
34-22 on March 12, 2009, but it did not proceed to a vote within the House. See Senate Vote
216, GA. GEN. ASSEMB., http://www1.legis.ga.gov/legis/2009_10/votes/sv0216.htm (last
visited Apr. 16, 2011).
71
2004 PRESIDENT’S COUNCIL REPORT, supra note 39, at 72.
72
See, e.g., 2008 Guidelines for Gamete and Embryo Donation: A Practice Committee Report,
90 FERTILITY & STERILITY S30, S30 (Nov. 2008) [hereinafter 2008 Guidelines for Gamete and
Embryo Donation]; Ethics Committee of the American Society of Reproductive Medicine,
Disposition of Abandoned Embryos, 82 FERTILITY & STERILITY S253 (Sept. 2004); Guidelines on
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B. Gametes
Although the government has occasionally asserted authority to
regulate specific practices,74 gametes (sperm and ova) remain largely
unregulated by both the federal government and states.75 The FDA is
mainly concerned with keeping infectious reproductive tissue out of the
market through regulations on screening, processing, and record
keeping.76
1.

Federal Regulation of Gametes

Semen and other reproductive material, including oocytes, are
considered HCT/Ps: Human Cells, Tissues, and Cellular and TissueBased Products regulated by the FDA.77 As such, they are subject to
rules designed to prevent communicable diseases.78 A key question is
whether synthetic gametes should be
regulated solely under 21 C.F.R. Part 1271, the
regulations
to
prevent
communicable
disease
transmission authorized by section 361 of the Public
Health Service Act. . . . [or] as biological products, drugs,
or devices under section 351 of the Public Health Service
Act and/or the Food Drug and Cosmetic Act.79

Number of Embryos Transferred, 86 FERTILITY & STERILITY S51 (2006); Preconception Gender
Selection for Nonmedical Reasons, 75 FERTILITY & STERILITY 861 (May 2001); ; see also Michael J.
Malinowski, Choosing the Genetic Makeup of Children: Our Eugenics Past—Present, and
Future?, 36 CONN. L. REV. 125, 185–87 (2003) (identifying additional professional
guidelines).
73
See 2004 PRESIDENT’S COUNCIL REPORT, supra note 39, at 175. But see LA. REV. STAT.
ANN. § 9:128 (2008) (requiring clinics to adhere to professional guidelines).
74
See infra Part III.B.2 (discussing the FDA’s claim of regulatory authority over
ooplasmic transfer).
75
See infra Parts III.B.1, III.B.3 (discussing federal and state regulation of gametes).
76
Yuen, supra note 14, at 554.
77
Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment
Registration and Listing, 66 Fed. Reg. 5447, 5448 (Jan. 19, 2001) (to be codified at 21 C.F.R.
pts. 207, 807, 1271).
78
21 C.F.R. § 1271.75 (2010). Sections 1271.85(a)–(c) of the regulations require
anonymously donated gametes to be tested for the following diseases:
human
immunodeficiency virus, type 1; human immunodeficiency virus, type 2; hepatitis B virus;
hepatitis C virus; treponema pallidum; human T-lymphotropic virus, type I; human Tlymphotropic virus, type II; cytomegalovirus (“CMV”); chlamydia trachomatis; and
neisseria gonorrhea. 21 C.F.R. § 1271.85(a)–(c).
79
Letter to Sponsors/Researchers—Human Cells Used in Therapy Involving the Transfer of
Genetic Material by Means Other Than the Union of Gamete Nuclei, U.S. FOOD & DRUG ADMIN.
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FDA Regulation of Oocytes

The FDA has asserted its jurisdiction to control research involving
oocyte nuclear transfer and a related procedure, ooplasmic transfer. In
1998, researchers used oocyte nuclear transfer by
removing the nucleus from a woman’s egg and injecting
it into a donor’s egg, from which the nucleus had
already been removed. The technique was meant to
help older women whose infertility was believed linked
to problems with the cytoplasm of her own eggs. The
reconstructed egg was then fertilized with the father’s
sperm and implanted in the patient’s womb. (This is not
cloning, because an adult cell is not involved, but the
nuclear transfer process is the same.)80
The researchers “gave their findings to doctors in China because
regulations imposed by the [FDA] in 2001 made it too difficult to
continue the research in the United States.”81
Ooplasmic transfer was developed by Dr. Jacques Cohen of the Saint
Barnabas Medical Center in New Jersey. Rather than transferring the
nuclei of the intended mother into the denucleated donor egg, as in
oocyte nuclear transfer, the ooplasm (or cytoplasm) from the donor egg
is “injected into the ooplasm of another woman whose embryos
previously failed to develop.”82 As with oocyte nuclear transfer, a child
born using ooplasmic transfer has genetic material from three sources:
the donor egg, the intended mother’s egg, and the sperm.83
In July 2001, the FDA sent a letter to the New Jersey researchers
regarding the ooplasmic transfer which stated the following:

(May 6, 2009), http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm
105852.htm.
80
HENRY C. LEE & FRANK TIRNADY, BLOOD EVIDENCE: HOW DNA IS REVOLUTIONIZING
THE WAY WE SOLVE CRIMES 318 (2003).
81
Denise Grady, Pregnancy Created Using Egg Nucleus of Infertile Woman, N.Y. TIMES, Oct.
14, 2003, at A22, http://query.nytimes.com/gst/fullpage.html?res=980DE4D7113FF937A
25753C1A9659C8B63&pagewanted=all.
82
Anne Drapkin Lyerly, Marking the Fine Line: Ethics and the Regulation of Innovative
Technologies in Human Reproduction, 11 MINN. J. L. SCI. & TECH. 685, 701 (2010). For
additional information on ooplasm transfer, see also, BIOLOGICAL RESPONSE MODIFIERS
ADVISORY COMM., DEP’T OF HEALTH & HUMAN SERVS., BRIEFING DOCUMENT FOR DAY 1,
MAY 9, 2002, OOPLASM TRANSFER AS METHOD TO TREAT FEMALE INFERTILITY, [hereinafter
BRMAC, BRIEFING DOCUMENT], available at http://www.fda.gov/OHRMS/DOCKETS/
ac/02/briefing/3855B1_01.pdf.
83
Javitt & Hudson, supra note 10, at 1226; see also LEE & TIRNADY, supra note 80, at 318.
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We want to advise you that the Food and Drug
Administration (FDA) has jurisdiction over human cells
used in therapy involving the transfer of genetic
material by means other than the union of gamete
nuclei.
Examples of such genetic material include, but are not
limited to:
•
•
•
•

cell nuclei (e.g., for cloning),
oocyte nuclei,
ooplasm, which contains mitochondrial genetic
material, and
genetic material contained in a genetic vector,
transferred into gametes or other cells.

The use of such genetically manipulated cells (and/or
their derivatives) in humans constitutes a clinical
investigation and requires submission of an
Investigational New Drug application (IND) to FDA.
We wish to inform you of the FDA regulatory process
governing clinical investigations, which includes
requirements applicable to manufacturing processes, the
study of the safety and efficacy of such cells, and the
protection of human participants in such studies. We
can advise you whether or not your activities require
submission of an IND. If what you are doing or plan to
do does require an IND, we would be pleased to provide
you with information and guidance regarding filing
84
such an application.
Would a synthetic gamete constitute the “use of such genetically
manipulated cells (and/or their derivatives) in humans”? Arguably not.
Synthetic sperm or ova would contain chemically created DNA, not
human DNA, and thus would be outside of the banned procedures cited
in the letter. The use of a synthetic gamete avoids the problem of
“heteroplasmy,” that is, the mixing of ooplasm, and specifically
mitochondria, from more than one individual:
According to the FDA, “it is clear that stringent
mechanisms have evolved to insure homogeneity of
84

See Letter to Sponsors/Researchers, supra note 79.
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mitochondrial genotypes at the initiation of human
development. The FDA has concerns about the safety of
perturbing this process.” Moreover, ooplasm transfer
“changes the genetic makeup of the resulting offspring.
Appropriate follow-up of children born after ooplasm
transfer and their progeny must therefore be considered
carefully.”85
A broader reading of the FDA’s regulations on HCT/Ps, however,
might apply to research on synthetic gametes. The regulations at 21
C.F.R. § 1271.10 include a list of requirements for Public Health Service
Act section 361 products, including gametes and embryos, which are to
be subject to less stringent regulation (with no FDA pre-market review) if
the HCT/P is “minimally manipulated.”86 Combining sperm with ova
through intracytoplasmic sperm injection (“ICSI”),87 for example, has
fallen into this category requiring no review. In our case, using ICSI to
inject synthetic sperm into a human ovum could be within the reach of
section 361; the same would be true for injecting human sperm into a
synthetic ovum.
Several articles have urged the FDA to expand the scope of their
review to include assisted reproduction, especially IVF, but so far to no
avail.88 If the FDA disagreed and chose to categorize the synthetic
gametes under section 351 of the Public Health Service Act, then the
research would be treated as an investigational new drug and subject to
the same extensive testing as a new pharmaceutical. Section 351
products are those that do not meet the Section 1271.10 requirements and
are regulated like drugs and/or biological products, requiring FDA premarket review and approval. They represent more risk and include gene
therapy products, human cloning, and human cells used in therapy
involving the transfer of genetic material. The synthetic cell could fit
into this more regulated category, although it generally refers to somatic
(i.e., non-gamete) cell therapies like cloning and gene therapy that
typically involve replacing defective genes. Still, the argument can be
made that the stringent regulations that apply when DNA is being
manipulated demonstrate a risk-based intent and should therefore apply
where DNA is being manufactured.
Javitt & Hudson, supra note 10, at 1227 (footnotes omitted) (quoting BRMAC, BRIEFING
DOCUMENT, supra note 10, at 4).
86
21 C.F.R. § 1271.10(a)(1) (2010).
87
Intracytoplasmic sperm injection, developed in the 1990s, involves inserting a single
sperm into an egg and then implanting the resulting embryo.
88
See, e.g., Baruch, supra note 42, at 262–63; King, supra note 38, at 288–89; Malinowski,
supra note 74, at 219–20.
85

https://scholar.valpo.edu/vulr/vol45/iss4/3

Knapland: Synthetic Cells, Synthetic Life, and Inheritance

2011]
3.

Synthetic Cells, Synthetic Life, and Inheritance

1379

State Regulation of Gametes

State legislation on gametes is concerned largely with the sale of
sperm or eggs for valuable consideration, ensuring informed consent
before donation, and resolving issues of property ownership of
deposited gametes. New York, for example, broadly prohibits the sale of
tissue for valuable consideration.89 Other states specifically ban the sale
of human gametes for certain purposes,90 while Florida permits only
“reasonable compensation” for donation.91 Some states have enacted
laws requiring informed consent before gametes can be donated to
research,92 and some criminalize use that is inconsistent with the gamete
provider’s purpose.93 Finally, some states address issues of parentage94
or the disposition of gametes in the event of death or divorce.95
N.Y. PUB. HEALTH LAW § 4364(5) (McKinney 2002) (“No bank or storage facility shall
sell or otherwise transfer tissue for valuable consideration. Valuable consideration shall
not include reasonable costs associated with the procurement, processing, storage and
distribution of tissue.”).
90
See CAL. HEALTH & SAFETY CODE § 125350 (West Supp. 2010) (prohibiting the sale of
human oocytes “for the purposes of medical research or development of medical
therapies”); CONN. GEN. STAT. ANN. § 19a-32d(c)(3) (West Supp. 2010) (“A person who
elects to donate for stem cell research purposes any . . . unfertilized human eggs or human
sperm . . . shall not receive direct or indirect payment for such . . . unfertilized human eggs
or human sperm.”); IND. CODE ANN. § 35-46-5-3(a) (West Supp. 2010) (criminalizing the
purchase or sale of human ova); LA. REV. STAT. ANN. § 9:122 (2008) (prohibiting the sale of
human ova).
91
FLA. STAT. ANN. § 742.14 (West 2010) (“Only reasonable compensation directly related
to the donation of eggs, sperm, and preembryos shall be permitted.”).
92
See, e.g., CAL. HEALTH & SAFETY CODE § 125335(a) (“Prior to obtaining informed
consent from a subject for [assisted oocyte production (“AOP”)] or any alternative method
of ovarian retrieval on a subject for the purpose of procuring oocytes for research or the
development of medical therapies, a physician and surgeon shall provide to the subject a
standardized medically accurate written summary of health and consumer issues
associated with AOP and any alternative methods of oocyte retrieval.”); CONN. GEN. STAT.
ANN. § 19a-32d(c)(3) (“A person who elects to donate for stem cell research purposes
any . . . unfertilized human eggs or human sperm shall provide written consent for that
donation . . . .”).
93
CAL. PENAL CODE 367g(a) (West 2010) (“It shall be unlawful for anyone to knowingly
use sperm, ova, or embryos in assisted reproduction technology, for any purpose other
than that indicated by the sperm, ova, or embryo provider’s signature on a written consent
form.”).
94
See, e.g., TEX. FAM. CODE ANN. § 160.706(a) (West 2008) (“If a marriage is dissolved
before the placement of eggs, sperm, or embryos, the former spouse is not a parent of the
resulting child unless the former spouse consented in a record . . . .”); Id. § 160.707 (“If a
spouse dies before the placement of eggs, sperm, or embryos, the deceased spouse is not a
parent of the resulting child unless the deceased spouse consented in a record . . . .”).
95
FLA. STAT. ANN. § 742.17 (“A commissioning couple and the treating physician shall
enter into a written agreement that provides for the disposition of the commissioning
couple’s eggs, sperm, and preembryos in the event of a divorce, the death of a spouse, or
any other unforeseen circumstance.”).
89
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None of these statutes would limit creating synthetic gametes as
long as researchers did not violate laws on informed consent or valuable
consideration for the human gametes analyzed for their DNA sequences.
As is the case with embryos, the professional societies’ limitations on
buying and selling gametes are voluntary and thus would be applicable
only in cases where a state has mandated compliance with a professional
society’s guidelines.96 The parentage statutes, however, may apply to
the successful use of a synthetic gamete, an issue to which we now turn.
IV. PARENTAGE AND INHERITANCE FOR CHILDREN WITH SYNTHETIC
GAMETES
Assuming that the practical and regulatory problems are resolved,
and a child is created using synthetic gametes, who are the parents?
Traditional notions of “genetic parents” and “birth mothers”97 may break
down once we have the ability to create sperm or ova entirely from
chemicals.
The 2008 Uniform Probate Code (“UPC”) sections on assisted
reproduction answer the parentage questions fairly easily because the
UPC looks at intended parents rather than genetic parents. First,
consider three scenarios with two intended parents, both alive:
1.

Synthetic sperm and the ovum of the birth mother: UPC
section 2-120 declares that the birth mother is the
98
child’s mother, as do most state statutes. The key
question is, who is the father? If the birth mother is
married, then her husband is presumed to have
consented to be the father, a presumption that can
99
If
be rebutted by clear and convincing evidence.
the birth mother is not married, then consent to
assisted reproduction with the intent to be the
parent of the resulting child can be shown by a
signed record or functioning as a parent no later
100
than two years after the child’s birth.

2004 PRESIDENT’S COUNCIL REPORT, supra note 39, at 178; see, e.g., 2008 Guidelines for
Gamete and Embryo Donation, supra note 72, at S30.
97
“Birth mother” is defined as “a woman, other than a gestational carrier under Section
2-121, who gives birth to a child of assisted reproduction. The term is not limited to a
woman who is the child’s genetic mother.” UNIF. PROBATE CODE § 2-120(a)(1) (amended
2008), 8 U.L.A. 58 (Supp. 2010).
98
Id. § 2-120(c).
99
Id. § 2-120(h)(1).
100
Id. § 2-120(f)(1), (f)(2)(A).
96
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Synthetic sperm and donated human ovum where the
intended mother gives birth: The UPC treats this
scenario the same as the first, because the UPC looks
at the intended parents rather than the genetic
parents. The ovum donor is not a parent, so she is
out of the equation.101 A parent-child relationship
exists with the birth mother and may exist with the
birth mother’s husband or partner as in scenario
one. The problem is the existing statutes in many
states that have not been updated to include ova
donations. Some states have statutes modeled after
the 1973 Parentage Act that stipulate that a donor
who gives sperm to a licensed physician for use by a
married woman is not the father of the resulting
child.102 In one of these states, the ovum “donor”
might still be able to claim she is the child’s mother
because her donation did not comply with the
statutory language.103

3.

Human sperm and synthetic ovum where the intended
mother gives birth: There are no complications here.
The birth mother is presumed to have a parent-child
relationship, which is what the parties intend. For
the father, if he is married to the birth mother, he is
the father because his sperm was used during his
lifetime,104 so long as the couple did not divorce
before placement (implantation) of the sperm, eggs,
or embryos, and he did not withdraw his consent, in
writing, before the placement.105 If the birth mother
is single, the other intended parent must show his
consent through the means detailed in scenario one.

1381

Id. § 2-120(b).
See, e.g., MINN. STAT. ANN. § 257.56(2) (West 2007); MO. ANN. STAT. § 210.824 (West
2010); MONT. CODE ANN. § 40-6-106 (2009); NEV. REV. STAT. ANN. § 126.061 (LexisNexis
2010); WISC. STAT. ANN. § 891.40 (West 1997 & Supp. 2010).
103
See, e.g., Jhordan C. v. Mary K., 179 Cal. App. 3d 386, 393 (1986) (noting that the
California statute is limited “to instances in which the semen is provided to a licensed
physician.... Accordingly, [the California statute] by its terms does not apply to the present
case” in which sperm was provided directly to the woman, and thus the sperm “donor”
was the legal father). Accord, Turchyn v. Cornelius, 1999 Ohio App. LEXIS 4129 (1999).
104
UNIF. PROBATE CODE § 2-120(d).
105
Id. § 2-120(i), (j).
101
102
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The next scenario involves the use of a gestational carrier and so the
intended mother is not the birth mother. Under the UPC, the gestational
carrier is not a parent of the resulting child unless a court so orders, or in
cases where the gestational carrier is the genetic mother and no one else
has a parent-child relationship.106
4.

Gestational carrier is birth mother with synthetic sperm
and/or ovum: Because of cases such as In re Baby
M,107 gestational carriers are rarely genetically
related to the child; either the intended mother’s
ovum or a donated ovum is implanted. In several
states, the birth mother is conclusively presumed to
be the child’s mother, which is not what the parties
intend. Statutes in two states that conclusively
presumed the gestational carrier to be the child’s
mother
have
been
struck
down
as
unconstitutional.108 If the gestational carrier is not
the mother, then the UPC would treat the intended
parents as the legal parents of the child, as in our
previous scenarios.

Finally, we must consider the parentage issues if either the
implantation of the embryo containing a synthetic gamete, or the
gestational agreement concerning such an embryo, has occurred after
one or both of the intended parents has died, commonly called
postmortem conception (“PMC”).
PMC is the subject of numerous court cases, statutes, and newspaper
articles. Courts in at least nine jurisdictions have adjudicated cases

Id. § 2-121(c).
In re Baby M., 537 A. 2d 1227 (1988) (surrogate Mary Beth Whitehead was also the
genetic mother, Id. at 1234; New Jersey Supreme Court declared surrogate was the mother
of the resulting child, Id. at 1234). C.f. Johnson v. Calvert, 851 P. 2d 776 (Cal. 1993)
(surrogate was not the child’s genetic mother, Id. at 778; court noted that “although the
[Uniform Parentage] Act recognizes both genetic consanguinity and giving birth as means
of establishing a mother and child relationship, when the two means do not coincide in one
woman, she who intended to procreate the child--that is, she who intended to bring about
the birth of a child that she intended to raise as her own--is the natural mother under
California law. Id. at 782.
108
See J.R. v. Utah, 261 F. Supp. 2d 1268, 1289 (D. Utah 2002); Soos v. Superior Court of
the State of Ariz., 897 P.2d 1356, 1361 (Ariz. Ct. App. 1994) (holding that the surrogate
statute violated the Equal Protection Clause). In a third state, the court avoided the
constitutional problem by extending its paternity statute to allow a gestational carrier to
deny maternity. In re Roberto d.B., 923 A.2d 115, 124 (Md. 2007).
106
107
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involving PMC children.109
Several states have enacted statutes
requiring written consent to be a parent of a PMC child;110 two states
have statutes that eliminate some or all claims of a PMC child.111 If the
decedent’s gametic material is used to conceive the child, the usual
issues of parentage and inheritance of a PMC child will come into play.
The added complexity here occurs when the decedent is not the genetic
parent. The consent issues can be analogized to a decedent’s consent for
assisted reproduction in which donated gametes are used, because in
either case, synthetic gamete or donated gamete, the decedent has no
biological tie to the child. The UPC provides that, in cases where no
gestational carrier is used, the decedent’s intent to be a parent can be
shown by a signed record or by clear and convincing evidence of such
intent.112 If the birth mother is the decedent’s surviving spouse and no
divorce proceedings were pending at the time of the decedent’s death,
then the decedent is presumed to have consented to be a parent of the
PMC child.113 However, if a gestational carrier is used, UPC section 2-

109
Courts in New Jersey, Massachusetts, Arizona, and New York have held that state law
allows a decedent to be named the parent of a PMC child if certain conditions are met. See
Gillett-Netting v. Barnhart, 371 F.3d 593, 599 (9th Cir. 2004); Woodward v. Comm’r of Soc.
Sec., 760 N.E.2d 257, 272 (Mass. 2002); In re Estate of Kolacy, 753 A.2d 1257, 1263-64 (N.J.
Super. Ct. Ch. Div. 2000); In re Martin B., 841 N.Y.S. 2d 207, 211 (N.Y. Sur. Ct. 2007). Courts
interpreting the state law of California, Arkansas, New Hampshire California and Virginia
have held that a PMC child cannot inherit from a decedent. Vernoff v. Astrue, 568 F.3d
1102, 1112 (9th Cir. 2009); Finley v. Astrue, 270 S.W.3d 849, 850 (Ark. 2008); Khabbaz v.
Comm’r of Soc. Sec., 930 A.2d 1180, 1182 (N.H. 2007); Schafer v. Astrue, 2011 U.S. App.
LEXIS 7456 at 9 (4th Cir. 2011). Florida law states that a PMC child inherits only if
provided for in the decedent’s will, and one court has ruled that absent such testamentary
provision a PMC child cannot inherit in intestacy and thus is ineligible for Social Security
survivor benefits. Stephen v. Comm’r of Soc. Sec., 386 F. Supp. 2d 1257, 1265 (M.D. Fla.
2005); c.f. Capato v. Comm’r of Soc. Sec., 631 F.3d 626, 632 (3rd Cir. 2011) (PMC child who
is undisputed biological child of decedent is his child for purposes of Social Security Act,
notwithstanding Florida law).
110
See ALA. CODE § 26-17-707 (LexisNexis 2009); CAL. PROB. CODE § 249.5 (West Supp.
2011); COLO. REV. STAT. ANN. § 19-4-106(8) (West 2005 & Supp. 2010); DEL. CODE ANN. tit.
13, § 8-707 (2009); FLA. STAT. ANN. § 742.17(4) (West 2010); LA. REV. STAT. ANN. § 9:391.1(A)
(2008); N.M. STAT. ANN. § 40-11A-707 (LexisNexis Supp. 2010); N.D. CENT. CODE § 14-20-65
(2009); TEX. FAM. CODE ANN. § 160.707 (West 2008); UTAH CODE ANN. § 78B-15-707
(LexisNexis 2008); WASH. REV. CODE ANN. § 26.26.730 (West 2005); WYO. STAT. ANN. § 14-2907 (2009).
111
See N.Y. EST. POWERS & TRUSTS LAW § 5-3.2(b) (McKinney 1999 & Supp. 2011) (noting
that a PMC child has no claim as a pretermitted heir, but may take in other circumstances);
VA. CODE ANN. § 20-164 (2008) (stating that any child born more than ten months after the
death of a parent is not recognized as the child of that parent and thus cannot inherit in
intestacy or by will).
112
UNIF. PROBATE CODE § 2-120(f).
113
Id. § 2-120(h)(2).

Produced by The Berkeley Electronic Press, 2011

Valparaiso University Law Review, Vol. 45, No. 4 [2011], Art. 3

1384 VALPARAISO UNIVERSITY LAW REVIEW

[Vol. 45

121 requires that the decedent’s sperm or eggs be used, and thus the
decedent would not be a parent of the PMC child. 114
The UPC, if enacted, would resolve the question of parenthood in
favor of the intended parents, but to date only two states have enacted
the UPC section on assisted reproduction.115 Many states have not
updated their statutes to address the donation of ova; others refuse to
enforce gestational carrier agreements. In these states, the lack of a
genetic parent due to the use of synthetic gametes may create problems
for courts. Similarly, these states may declare the gestational carrier to
be the mother of the child regardless of her genetic connection to the
child.
V. CONCLUSION
In a paper published in 1971, seven years before he and a colleague
successfully used in vitro fertilization for the first time to create a human
child, Dr. Edwards warned of the possibility of the rise of gestational
surrogacy, egg banks, gene splicing, sexing blastocysts, and artificial
wombs.116 We have yet to address all of Dr. Edwards’ concerns over
thirty years after Louise Brown was born in 1978. Now that Venter’s
announcement has opened the door to synthetic gametes, it is time to
start thinking about both regulatory issues and parentage issues for
synthetic sperm, ova, and embryos. Should existing regulations of
gametes and embryos be updated to include those created chemically?
We have at least three choices: we can allow researchers to proceed in
the same manner as PGD and other techniques used in assisted
reproduction with little regulation or oversight; we can analogize to
oocyte transfer or cloning and stop all research until the safety issues
have been resolved; or we can allow research with more oversight.
114
By the time we have successfully manufactured synthetic gametes, we may have also
perfected an artificial womb and as a result have no need for a gestational carrier. See
Gretchen Reynolds, Artificial Wombs: Will We Grow Babies Outside Their Mothers’ Bodies?,
POPULAR SCI. (Aug. 1, 2005, 2:00 pm), http://www.popsci.com/scitech/article/200508/artificial-wombs (quoting Hung-Ching Liu, the director of the Reproductive Endocrine
Laboratory at the Center for Reproductive Medicine and Infertility at Cornell University,
who said that an artificial human womb may be available in “‘10 years, maybe, or a little
more . . . . It could take as much as 50 years, but I’m very hopeful that this is possible.’”).
115
Uniform Probate Code § 2-120 (child conceived by assisted reproduction other than
child born to gestational carrier) has been adopted in three states: Colorado, Minnesota
and North Dakota. COLO. REV. STAT. 15-11-120; MINN. STAT. ANN. 524.2-120 (Subd. 7); N.D.
CENT. CODE 30.1-04-19. Uniform Probate Code § 2-121 (child born to gestational carrier)
has been adopted in Colorado and North Dakota. COLO. REV. STAT. 15-11-121; N.D. CENT.
CODE 30.1-04-20.
116
Robert G. Edwards & David J. Sharpe, Social Values and Research in Human Embryology,
231 NATURE 87, 87–91 (1971).
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Choosing the first path may bring technologies into the marketplace
before they are fully tested.117 If we choose the second path, it is difficult
to foresee how the safety concerns will be addressed. The traditional
way is to do research on animals, but experience has shown us that
humans do not react in precisely the same way as animals, and the
outcomes can be unpredictable.118 Scholarly discussion urging more
regulation and oversight of ART could be applied to the issue of
synthetic gametes to determine the appropriate level of oversight.119
There is a second critical issue: once a synthetic gamete has been
created and used to create a living child, who are the child’s parents?
Should we move to a regime of intended parents for synthetic
reproduction, as the UPC has already urged for children of assisted
reproduction? Such a move would require a fundamental shift in the
way states approach parentage, away from biological and genetic
markers and toward intent (or consent) to be a parent of the resulting
child. For reasons of public policy, consent to be a parent is presumed
when one engages in coitus. Even if the child was conceived under
criminal or fraudulent circumstances (for example, a false promise of
infertility), the progenitors are still the parents of the resulting child.
In contrast, when a child is conceived using assisted reproduction,
the public policy considerations are quite different, and consent (or
117
See, e.g., Anne Adams Lang, Doctors Are Second-Guessing The ‘Miracle’ of Multiple Births,
N.Y. TIMES, June 13, 1999, www.nytimes.com/1999/06/13/health/doctors-are-secondguessing-the-miracle-of-multiple-births.html?src=pm (noting that the incidence of multiple
births has quadrupled since the mid-1980s, largely because of the use of ART, and that
almost all are born premature with various physical problems and a highly increased
mortality rate); Peres, supra note 32, at C1 (describing lawsuit against a medical center that
claimed it could screen a woman’s eggs for the genes that carry cystic fibrosis using PGD
where the resulting child had cystic fibrosis); Gladys B. White, A Devil’s Bargain for the
Infertile: Fertility Treatments Are Causing More Multiple Births, Leading To Risks to Mothers and
Newborns, CHI. TRIB., June 24, 2007, at C9 (stating the same).
118
See, e.g., Daniel G. Hackam & Donald A. Redelmeier, Translation of Research Evidence
From Animals to Humans, 296 J. AM. MED. ASS’N 1731, 1732 (2006) (“Only about a third of
highly cited animal research translated at the level of human randomized trials.”). Trisha
Gura states that
many thousands of drugs have shown activity in either cell or animal
models, but only 39 that are used exclusively for chemotherapy, as
opposed to supportive care, have won approval from the U.S. Food
and Drug Administration. “The fundamental problem in drug
discovery for cancer is that the model systems are not predictive at
all.”
Trisha Gura, Systems for Identifying New Drugs Are Often Faulty, 278 SCI. 1041, 1041 (1997)
(quoting Alan Oliff, the former executive director for cancer research at Merck Research
Laboratories).
119
See, e.g., Baruch, supra note 42, at 267–70; King, supra note 38, at 288–89; Malinowski,
supra note 72, at 197–222.
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rather, intent) to be the parent needs to be established. In many instances
involving assisted reproduction, the biological parent does not intend to
be the parent of the child. Whenever donor sperm, ova, or embryos are
used in assisted reproduction, the donor has usually agreed not to seek
parentage rights in a resulting child. Similarly, with gestational carrier
agreements, while the carrier is biologically connected to the child as the
birth mother, she has usually agreed she will not claim to be the
resulting child’s mother (although her agreement may not be enforceable
in all states). In addressing assisted reproduction with donor gametes or
gestational carriers, the UPC attempts to determine the parents where
too many possibilities abound; one California case identified six different
possible parents of the resulting child.120 With synthetic gametes, the
problem may instead be too few possible human parents because at least
one genetic parent will be out of the equation.
The two UPC sections on assisted reproduction have been adopted
in only two states despite being promulgated in 2008.121 Although some
states may have hesitated because they do not enforce gestational carrier
arrangements, this does not explain why they have failed to address the
use of assisted reproduction in other ways, such as with donor gametes.
As we move toward the possibility of synthetic gametes, the debate over
genetic and biological parents versus intended parents will demand
resolution.

120
Buzzanca v. Buzzanca, 72 Cal. Rptr. 2d. 280, 282-88 (gestational carrier and her
husband, egg donor, sperm donor, and the genetically unrelated intended parents) (Cal. Ct.
App. 1998).
121
Supra note 115.
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